Clinical trials: Anal Cancer
Anal Cancer, Colorectal Cancer
Anal Sphincter Prosthesis in Treating Patients Who Are Undergoing Surgery for Anal or Rectal Cancer
RATIONALE: An anal sphincter prosthesis may replace the need for a permanent colostomy and may improve the quality of life of patients who are undergoing surgery for anal or rectal cancer.
- Conditions
- Anal Cancer, Colorectal Cancer, Perioperative/Postoperative Complications
- Trial name
- NCT00059891
- Testing
- conventional surgery, management of therapy complications
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Prostate Cancer (Post Prostatectomy), Anal Cancer
Assessment of New Radiation Oncology Technologies and Treatments
The Trans Tasman Radiation Oncology Group (TROG) has been commissioned by the Department of Health and Ageing to undertake a project to assess new Radiation Oncology Technology and Treatments.
- Conditions
- Prostate Cancer (Post Prostatectomy), Anal Cancer, Nasopharyngeal Cancer, Intermediate Risk Prostate Cancer
- Trial name
- ANROTAT (NCT01379872)
- Testing
- Non-Interventional Study
- Where
- 15 sites in Australia
- Volunteers
- 138 people
- Sponsor
- Trans Tasman Radiation Oncology Group
Anal Cancer
Radiation Dosimetry Study Comparing 2 Different Patient Setups in Anal/Rectal Cancer Patients
The study compares two patient setups (Standard Prone vs. Genital Drop Technique) with identical radiation treatment technique and parameters.
- Trial name
- NCT00693173
- Where
- United States
- Volunteers
- 14 people
- Sponsor
- The University of Texas Medical Branch, Galveston
Anal Cancer
SGN-00101 in Preventing Anal Cancer in Patients With HIV Who Have Anal Neoplasia
Phase I/II trial to study the effectiveness of SGN-00101 in preventing anal cancer in HIV-positive patients who have high-grade anal neoplasia.
- Trial name
- NCT00052897
- Testing
- HspE7
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- National Cancer Institute (NCI)
Squamous Cell Carcinoma of Anal Canal
Nimotuzumab With Radiotherapy in the Treatment of Anal Canal Cancers
The objective of this study is to demonstrate the feasibility of using Nimotuzumab and radiation in the treatment of squamous cell carcinomas of the anal canal in order to achieve a 65% local control rate with a better toxicity…
- Trial name
- NCT01382745
- Testing
- Nimotuzumab, Intensity Modulated Radiation Therapy (IMRT)
- Where
- Canada
- Volunteers
- 1 people
- Sponsor
- Dr. Te Vuong
Adult Anaplastic Astrocytoma, Adult Anaplastic Ependymoma
Erlotinib in Treating Patients With Solid Tumors and Liver or Kidney Dysfunction
Phase I trial to study the effectiveness of erlotinib in treating patients who have metastatic or unresectable solid tumors and liver or kidney dysfunction.
- Conditions
- Adult Anaplastic Astrocytoma, Adult Anaplastic Ependymoma, Adult Anaplastic Oligodendroglioma, Adult Brain Stem Glioma
- Trial name
- NCT00030498
- Testing
- erlotinib hydrochloride, laboratory biomarker analysis
- Where
- United States
- Volunteers
- 75 people
- Sponsor
- National Cancer Institute (NCI)
Anal Cancer
Image Fusion PET, CT and 3D-ultrasound Examinations
CT-examinations are used in computer programs which are used in the planning of external radiation of cancers in the anal canal. In CT the structures of the anal canal are hardly visible.
- Trial name
- NCT00302094
- Where
- Denmark
- Volunteers
- 10 people
- Sponsor
- Copenhagen University Hospital, Rigshospitalet
Anal Cancer
Radiation Therapy, Mitomycin, and Either Fluorouracil or Cisplatin in Treating Patients With Locally Advanced Anal Cancer
RATIONALE: Drugs used in chemotherapy, such as mitomycin, fluorouracil, and cisplatin, use different ways to stop tumor cells from dividing so they stop growing or die.
- Trial name
- NCT00068744
- Testing
- cisplatin, fluorouracil, mitomycin C
- Where
- 24 sites in Belgium, Egypt and 5 more
- Volunteers
- 88 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Colorectal Neoplasms, Colon Cancer
Avastin/[18-F]-5-fluorouracil PET/CT Imaging Feasibility Project
To determine whether using a radiolabelled analog of 5-FU, [18F]-5-fluorouracil, for PET/CT imaging can visually demonstrate differential chemotherapy delivery to known tumor sites before and after administration of bevacizumab…
- Conditions
- Colorectal Neoplasms, Colon Cancer, Rectal Cancer, Anal Cancer
- Trial name
- NCT00661154
- Testing
- Bevacizumab
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- Stanford University
Anal Cancer, Colorectal Cancer
Interleukin-12 in Treating Patients With Cancer in the Abdomen
RATIONALE: Interleukin-12 may kill tumor cells by stimulating a person's white blood cells to kill cancer cells. PURPOSE: Phase I trial to study the effectiveness of interleukin-12 in treating patients with cancer in the abdomen.
- Conditions
- Anal Cancer, Colorectal Cancer, Gallbladder Cancer, Gastric Cancer
- Trial name
- NCT00003046
- Testing
- Recombinant Interleukin-12
- Where
- United States
- Volunteers
- 29 people
- Sponsor
- M.D. Anderson Cancer Center
Anal Cancer, Colorectal Cancer
Assessment of Symptom-Related Cytokines in Lung and Gastrointestinal (GI) Cancer Patients
Primary Objectives: To determine the feasibility of a study that would describe changes of certain circulating inflammatory cytokines (interleukin-1, 6, 8, 10, 12, and tumor necrosis factor-alpha [TNF] and symptoms related to…
- Conditions
- Anal Cancer, Colorectal Cancer, Esophageal Cancer, Gastric Cancer
- Trial name
- NCT00502502
- Testing
- Questionnaire
- Where
- United States
- Volunteers
- 205 people
- Sponsor
- M.D. Anderson Cancer Center
Anal, Colon, and Rectal Cancers, Colorectal Neoplasms
Phase I Vandetanib Plus Capecitabine, Oxaliplatin and Bevacizumab for Metastatic Colorectal Cancer
To determine the maximum tolerated dose of Vandetanib with a current standard first-line chemotherapy regimen, capecitabine and oxaliplatin without and then with bevacizumab for the first line treatment of metastatic colorectal…
- Conditions
- Anal, Colon, and Rectal Cancers, Colorectal Neoplasms, Colon/Rectal Cancer
- Trial name
- NCT00532909
- Testing
- Vandetanib, Capecitabine, Oxaliplatin
- Where
- United States
- Volunteers
- 13 people
- Sponsor
- Branimir Sikic
Gastrointestinal Neoplasms, Gynecologic Cancers
Collection of Biospecimen & Clinical Information in Patients w/ Gastrointestinal Cancers
We have an active research program in gastrointestinal cancers including clinical trials, epidemiologic, and translational studies.
- Conditions
- Gastrointestinal Neoplasms, Gynecologic Cancers, Gynecologic Cancers Cervical Cancer, Gastric (Stomach) Cancer
- Trial name
- NCT01031056
- Testing
- Blood Draw, Frozen Tumor Specimens
- Where
- United States
- Sponsor
- Stanford University
Anal Cancer, HIV Infections
Pilot Study to Determine the Safety and Efficacy of Gardasil Against the Human Papilloma Virus (HPV) in HIV-infected Men
This study will investigate the efficacy and safety of the quadrivalent vaccine (Gardasil) against the human papilloma virus (HPV) in HIV (human immunodeficiency virus) infected males.
- Trial name
- MIRB #862 (NCT00666107)
- Testing
- Gardasil
- Where
- United States
- Volunteers
- 150 people
- Sponsor
- Southern California Institute for Research and Education
Rectal Cancer, Colon Cancer
Assessment of Health Related Quality of Life in Patients Treated for Rectal Cancer
Treatment of rectal cancer often consists of surgical resection of the tumor. Chemotherapy and/or radiotherapy are frequently given before or after surgery.
- Conditions
- Rectal Cancer, Colon Cancer, Anal Cancer
- Trial name
- NCT00532987
- Testing
- Questionnaire
- Where
- United States
- Volunteers
- 22 people
- Sponsor
- Stanford University
Colorectal Neoplasms, Anal, Colon, and Rectal Cancers
Feasibility of Autologous Tumor Cell-TLR9 Agonist Vaccination for Metastatic Colorectal Cancer
Current therapies for metastatic colorectal cancer only prolong life for approximately 2 years. A more innovative therapy that prolongs life significantly or even cures is needed.
- Trial name
- NCT00780988
- Testing
- Autologous tumor cell + CpG vaccine, Autologous hematopoietic and immune cell rescue (transplantation)
- Where
- United States
- Sponsor
- Stanford University
Anal Cancer
Assessing Drivers and Barriers to Follow-Up Screening for Anal Cancer in Men Who Have Sex With Men
This study is designed to identify barriers that prevent men who have sex with men from receiving doctor-recommended annual follow-up screenings for anal cancer.
- Trial name
- NCT00501306
- Where
- United States
- Volunteers
- 195 people
- Sponsor
- Laser Surgery Care
Anal Canal HPV Infection Diagnosis, Anal Dysplasia Diagnosis
Hybrid Capture 2 Human Papiloma Virus (HPV) High-Risk Anal DNA Test
This is a study to determine if HC2 HPV testing in the anal canal can detect high-risk HPV and whether this aids in identifying individuals are risk for anal cancer or precancerous lesions.
- Conditions
- Anal Canal HPV Infection Diagnosis, Anal Dysplasia Diagnosis, Anal Cancer
- Trial name
- NCT01104181
- Testing
- HC2 collection kit with a swab or brush
- Where
- United States
- Volunteers
- 300 people
- Sponsor
- Laser Surgery Care
Anal Cancer
Predictive Value of FMISO-PET, FDG-PET-CT, DWI-MRI and DCE-MRI Scans for Patients With Anal Cancer Receiving Radiotherapy +/- Chemotherapy
The purpose of the study is to evaluate the predictive value of 18F-fluoromisonidazol-PET (FMISO-PET), 2-18F-fluoro-2-deoxy-d-glukose-PET-CT (FDG-PET-CT), Diffusion-Weighted Magnetic Resonance Imaging (DWI-MRI) and Dynamic…
- Trial name
- NCT01330186
- Testing
- FMISO-PET, FDG-PET-CT and Magnetic Resonance Imaging (MRI)
- Where
- Denmark
- Volunteers
- 50 people
- Sponsor
- Copenhagen University Hospital at Herlev
Ovarian, Melanoma
Safety and Immune Response to a Multi-component Immune Based Therapy (MKC1106-PP) for Patients With Advanced Cancer.
The present clinical trial is a dose comparison of a multi-component active immunotherapy designed to stimulate an immune reaction to specific tumor associated antigens which are highly expressed on a large number of solid…
- Conditions
- Ovarian, Melanoma, Renal, Prostate
- Trial name
- NCT00423254
- Testing
- PSMA/PRAME
- Where
- 5 sites in United States
- Volunteers
- 12 people
- Sponsor
- Mannkind Corporation